A randomized, phase III study (AGO-OVAR-9, GINECO-TCG, NSGO-OC-0102): gemcitabine-paclitaxel-carboplatin (TCG) versus paclitaxel-carboplatin (TC) as first-line treatment of ovarian cancer (OC): survival of FIGO stage I-IIA patients

Jørn Herrstedt (Lecturer)

Activity: Talks and presentationsTalks and presentations in private or public companies

Period29. May 2009
Event title45th Meeting ASCO: null
Event typeConference
Conference number45
LocationOrlando, United States